AYUR-VEDA BIO-DEVELOPMENT LIMITED COMPANY
Update：2026/11/12
Industries
Main Industry
Biotechnology
Main Product/Service
OBI Pharma’s product and technology portfolio focuses on antibody-drug conjugates (ADCs) and enabling platforms. Core proprietary technologies include GlycOBI® glycan-conjugation platform, EndoSymeOBI®, ThiOBI®, HYPrOBI™, which enable plug-and-play compat
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50775252
Status
Active
Number of Employees
0
Total capital
1,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
OBI Pharma, Inc., founded in 2002 with its headquarters and R&D center in Taiwan, and subsidiaries in the United States and Australia, is a global clinical-stage oncology company. The company focuses on innovative cancer therapies, aiming to develop first-in-class and best-in-class drugs under the “Made in Taiwan” branding, and to deliver new treatment options to patients with unmet medical needs worldwide.
The content above was translated by Ai
